📈 Will you get serious about investing in 2025? Take the first step with 50% off InvestingProClaim Offer

'Magnificent 7' bets drive hedge fund crowding to record high -Goldman Sachs

Published 11/21/2023, 12:12 PM
Updated 11/21/2023, 12:16 PM
© Reuters. FILE PHOTO: Four thousand U.S. dollars are counted out by a banker counting currency at a bank in Westminster, Colorado November 3, 2009.  REUTERS/Rick Wilking/File Photo
US500
-
MSFT
-
LLY
-
AMZN
-

By Bansari Mayur Kamdar and Nell Mackenzie

LONDON (Reuters) - Hedge fund crowding has hit its highest on record, as asset managers have upped their bets on the "Magnificent 7" tech stocks that have juiced up portfolio returns this year, Goldman Sachs said in a report on Tuesday.

Megacap growth and technology stocks accounted for 13% of the aggregate hedge fund long portfolio, twice their weight at the start of 2023, with companies like Microsoft (NASDAQ:MSFT) and Amazon.com (NASDAQ:AMZN) remaining popular long positions.

This has helped drive outsized returns for the funds.

Returns for the stocks Goldman Sachs has identified as the most popular hedge fund long positions have jumped 31% so far this year, compared to the 19% rise in the benchmark S&P 500 index.

However, as popular positions gain momentum, there is a growing risk of crowding, which reached its highest in the 22 years since Goldman started tracking the funds.

The Goldman report analysed the holdings of 735 hedge funds with $2.4 trillion of gross equity positions. It showed the average hedge fund held 70% of its long portfolio in its top 10 positions.

In stock markets generally, Goldman Sachs said that as the year went on, it was harder to find a contrarian stock trade as most stocks followed the flow of the markets.

The "stock picking" environment has deteriorated and many company names move in the same direction, or are correlated, the bank said.

"The market has had record low dispersion and hedge funds are paid to generate alpha, and excess returns. Unlike long-only that are effectively forced to be indexers," said family office investor Michael Oliver Weinberg.

"So if they are concentrated and making money that's what they should be doing," he added.

The AI frenzy drove the move in hedge funds to tech stocks, but volatility created by GLP-1 drugs like Ozempic led to hedge fund portfolio rotations in the third quarter towards healthcare, the report showed.

Eli Lilly (NYSE:LLY) topped Goldman's list for largest increase in hedge fund popularity, benefiting from the rising demand for weight-loss drugs.

Meanwhile, the report also showed short interest in stocks remained low, as hedge funds are increasingly using vehicles like exchange-traded funds and futures, rather than single stock shorts, to hedge their exposure.

© Reuters. FILE PHOTO: Four thousand U.S. dollars are counted out by a banker counting currency at a bank in Westminster, Colorado November 3, 2009.  REUTERS/Rick Wilking/File Photo

The $181 billion in ETF shorts accounted for 80% of gross hedge fund ETF exposure. In comparison, single-stock shorts constitute just 30% of gross single-stock positions, according to the Goldman Sachs data.

Microsoft and Amazon did not immediately respond to requests for comment. Eli Lilly declined to comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.